Asco abstracts will be released today at 6:00 eastern time .
It appears new information is to be released on Provenge compared to placebo patients who were not infused with Frovenge which should be consistent with earlier reports of 7.8 mths median survival. We can only hope this new abstract will be suffice for the company to inform patients based on 7.8 mths median survival and not the flawed number where Frovenge was used with the Placebo patients to lower the two groups survival difference to 4.1 mths.
I am not to sure your comments deserves a reply however many investors don't realize that Provenge had an overall median survival of 25.9 mths. vs. 18.4 mths for Xtandi patients. The company fails in its message to patients that Provenge has superior survival and is handicapped by the inadequacy of the 4.1 mths. I am hoping the time has come for the FDA and Dendreon to give patients the REAL STORY.